U.S.-EU Tariff Deal Seems Positive for Pharma Sector, But Questions Remain -- Market Talk

Dow Jones07-28

1044 GMT - The tariff deal between the U.S. and the European Union should send a positive signal to pharmaceutical investors who have been on the sidelines for the most exposed companies, but some details have yet to be announced, Barclays analysts say in a research note. Investors' base case was a 25% sector tariff and President Trump had threatened levies of 200%, so a baseline duty of 15% on pharma products imported from the EU should come as a relief, according to Barclays. Nevertheless, this assumes that any sector-specific tariffs from a probe the Trump administration launched wouldn't be added to the baseline of 15%, the analysts say. Press reports suggests this will be the case, and U.S. officials have indicated the outcome should come on Aug. 1, Barclays says. The Stoxx Europe 600 Health Care index rises 1%. (adria.calatayud@wsj.com)

(END) Dow Jones Newswires

July 28, 2025 06:44 ET (10:44 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment